Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.48 |
| ▸ | GLS2 | Q9UI32 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31216704 | 1.00 | PRKCA (0.48) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL31216700 | 1.00 | PRKCA (0.48) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL31216699 | 1.00 | PRKCA (0.48) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL31216717 | 1.00 | PRKCA (0.48) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL17627885 | 1.00 | PRKCA (0.48) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL11617657 | 0.98 | PRKCA (0.45) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL3217709 | 0.93 | PRKCA (0.43) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL31216708 | 0.87 | MAPT (0.50) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL31216727 | 0.87 | TSHR (0.44) | TSHRMAPTMAPK1FAAHLMNA | |
| SCHEMBL31216702 | 0.87 | MAPT (0.50) | PRKCAGLS2TSHRTRPV1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111566108-B | Heterocyclic compound and harmful arthropod control agent containing same | 住友化学株式会社 | 2023-03-28 | — | — | CN | disclosed |
| EP-1673328-B1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF UNSATURATED ALCOHOLS | DOW GLOBAL TECHNOLOGIES INC (US) | 2008-07-09 | — | — | EP | disclosed |
| US-7176336-B2 | Preparing 9-octadecene-7,12-diol by catalyzing methyl ricinoleate derived from a seed oil, in presence of a metathesis catalyst; improved yield; use in manufacture of surfactants and thermoplastic polyurethanes | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1673328-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF UNSATURATED ALCOHOLS | Dow Global Technologies Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040077-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF UNSATURATED ALCOHOLS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050080301-A1 | Process for the synthesis of unsaturated alcohols | DOW GLOBAL TECHNOLOGIES LLC | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080301-A1 | Process for the synthesis of unsaturated alcohols | FASN, SQLE, ALOX12 | PRKCA 2479/4885GLS2 3078/4885TSHR 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.